Your browser is no longer supported. Please, upgrade your browser.
Settings
NAVB Navidea Biopharmaceuticals, Inc. daily Stock Chart
NAVB [AMEX]
Navidea Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own37.40% Shs Outstand20.20M Perf Week104.92%
Market Cap28.30M Forward P/E- EPS next Y-0.47 Insider Trans225.77% Shs Float10.38M Perf Month257.14%
Income-11.20M PEG- EPS next Q-0.07 Inst Own4.30% Short Float5.12% Perf Quarter159.07%
Sales0.80M P/S35.38 EPS this Y59.90% Inst Trans413.68% Short Ratio0.34 Perf Half Y267.65%
Book/sh-0.09 P/B- EPS next Y-23.10% ROA-207.50% Target Price3.50 Perf Year79.86%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.49 - 3.50 Perf YTD98.41%
Dividend- P/FCF- EPS past 5Y30.80% ROI843.30% 52W High-28.57% Beta1.17
Dividend %- Quick Ratio0.80 Sales past 5Y-36.30% Gross Margin99.80% 52W Low410.20% ATR0.29
Employees13 Current Ratio0.80 Sales Q/Q275.40% Oper. Margin- RSI (14)87.32 Volatility28.81% 15.41%
OptionableYes Debt/Eq- EPS Q/Q45.30% Profit Margin- Rel Volume3.80 Prev Close2.43
ShortableYes LT Debt/Eq- EarningsMay 14 AMC Payout- Avg Volume1.58M Price2.50
Recom2.00 SMA20134.15% SMA50182.64% SMA200176.44% Volume5,523,760 Change2.88%
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
May-26-20 10:11AM  Company News for May 26, 2020 Zacks
May-22-20 08:35AM  Navidea Biopharmaceuticals stock rockets toward 13-month high on heavy volume after update trial data MarketWatch +91.34%
07:10AM  The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray Benzinga
May-21-20 04:30PM  Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis Business Wire
May-15-20 03:29AM  Edited Transcript of NAVB earnings conference call or presentation 14-May-20 9:00pm GMT Thomson Reuters StreetEvents +14.42%
May-14-20 04:01PM  Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results Business Wire
May-11-20 07:30AM  Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® Business Wire
May-07-20 07:00AM  Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update Business Wire +7.67%
Apr-22-20 07:30AM  Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic Business Wire
Apr-21-20 08:52AM  What You Must Know About Navidea Biopharmaceuticals, Inc.'s (NYSEMKT:NAVB) Beta Value Simply Wall St.
Mar-31-20 07:30AM  Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navideas Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates Business Wire
Mar-24-20 04:19PM  Edited Transcript of NAVB earnings conference call or presentation 11-Mar-20 9:00pm GMT Thomson Reuters StreetEvents
Mar-20-20 07:00AM  Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek® Business Wire
Mar-11-20 04:05PM  Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
03:00PM  Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-04-20 08:00AM  Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update Business Wire +7.92%
Feb-21-20 08:42AM  Insider Buying: John Scott Just Spent US$2.0m On Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Shares Simply Wall St.
Feb-14-20 11:56AM  Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards Business Wire +20.41%
07:28AM  Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding Business Wire
Feb-12-20 09:20AM  Investors Who Bought Navidea Biopharmaceuticals (NYSEMKT:NAVB) Shares Five Years Ago Are Now Down 97% Simply Wall St.
Dec-30-19 05:19PM  Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York Business Wire +6.89%
Dec-14-19 09:41AM  The of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), John Scott, Just Bought 11% More Shares Simply Wall St.
Dec-06-19 06:23PM  Navidea Biopharmaceuticals Announces $1.9 Million Private Placement Business Wire +10.32%
Dec-05-19 03:45PM  Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event Business Wire
Dec-02-19 02:08PM  Navidea Biopharmaceuticals Wins Summary Judgment in Ohio Business Wire +7.19%
Nov-19-19 10:41PM  Edited Transcript of NAVB earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:30AM  Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference Business Wire
Nov-13-19 07:38AM  What Kind Of Shareholders Own Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB)? Simply Wall St.
Nov-07-19 04:05PM  Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
07:30AM  Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies Business Wire
Oct-31-19 07:30AM  Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update Business Wire
Oct-29-19 07:30AM  Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis Business Wire +40.19%
Oct-14-19 03:42PM  Edited Transcript of NAVB earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Sep-06-19 04:05PM  Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-27-19 07:30AM  Navidea Biopharmaceuticals Announces Receipt of Notice of Award Business Wire
Aug-08-19 04:05PM  Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial Results Business Wire +6.12%
Aug-01-19 04:05PM  Navidea Biopharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update Business Wire
Jun-24-19 07:46AM  Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study Results Business Wire +7.70%
Jun-18-19 04:05PM  Navidea Biopharmaceuticals Announces Closing of Public Offering of Common Stock Business Wire
01:30PM  Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
Jun-17-19 05:16PM  Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study Business Wire
Jun-13-19 11:16PM  Navidea Biopharmaceuticals Prices $6.0 Million Public Offering of Common Stock Business Wire
05:31PM  Navidea Biopharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:24PM  Navidea Biopharmaceuticals Regains Direct Control of Intellectual Property Business Wire
May-08-19 06:28PM  Navidea: 1Q Earnings Snapshot Associated Press
04:05PM  Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
May-01-19 04:05PM  Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update Business Wire
Apr-26-19 07:30AM  Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (TB) Business Wire -10.59%
Apr-19-19 04:05PM  Navidea Biopharmaceuticals Announces Reverse Stock Split Business Wire
Apr-08-19 07:30AM  Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates Business Wire +21.43%
Apr-02-19 04:05PM  Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting Business Wire
Mar-22-19 05:08PM  Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates Business Wire
Mar-13-19 01:31PM  Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT Thomson Reuters StreetEvents -11.00%
Mar-07-19 04:05PM  Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-28-19 07:00AM  Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update Business Wire -7.04%
Feb-01-19 07:00AM  Navidea Biopharmaceuticals Announces Extension of NYSE American Listing Business Wire -8.42%
Jan-24-19 07:00AM  Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court Business Wire
Dec-07-18 06:55AM  Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek® Business Wire
Dec-04-18 12:17AM  Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -7.50%
Nov-29-18 04:35PM  Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors Business Wire +5.49%
04:30PM  Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer Business Wire
Nov-28-18 06:55AM  Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018 Business Wire
Nov-27-18 06:55AM  Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018 Business Wire
Nov-26-18 04:30PM  Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors Business Wire
Nov-15-18 07:40AM  Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 06:45PM  Navidea: 3Q Earnings Snapshot Associated Press
04:10PM  Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results Business Wire
Nov-01-18 07:00AM  Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update Business Wire +8.94%
Oct-31-18 05:30PM  Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation Business Wire +9.60%
Oct-30-18 04:30PM  Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American Business Wire
Oct-11-18 06:55AM  Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting Business Wire
Oct-08-18 05:00PM  Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum Business Wire
Sep-18-18 08:44AM  The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga +60.06%
Sep-17-18 05:30PM  Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program Business Wire
05:20PM  Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement Business Wire
Sep-04-18 10:24AM  Edited Transcript of NAVB earnings conference call or presentation 16-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-16-18 03:00PM  Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:47AM  What Does Navidea Biopharmaceuticals Incs (NYSEMKT:NAVB) Ownership Structure Look Like? Simply Wall St.
07:00AM  Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting Business Wire
Aug-15-18 05:47PM  Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American Business Wire -8.64%
Aug-08-18 07:05PM  Navidea: 2Q Earnings Snapshot Associated Press
06:05PM  Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results Business Wire
Jul-12-18 05:47PM  Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update Business Wire
Jun-14-18 05:37PM  Navidea to Host Moderated Q&A Webcast with Management Business Wire
May-30-18 04:30PM  Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention Business Wire
May-17-18 09:42PM  Edited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 05:09AM  Navidea: 1Q Earnings Snapshot Associated Press -5.66%
May-08-18 05:00PM  Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
May-07-18 04:05PM  Navidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith ACCESSWIRE
May-02-18 04:05PM  Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update Business Wire
Apr-16-18 07:01AM  Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit Business Wire
07:00AM  Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights Business Wire
Apr-05-18 07:00AM  Wired News EMA to Review Regenerons Marketing Authorization Application for Cemiplimab ACCESSWIRE -7.13%
Apr-03-18 12:48PM  Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial Business Wire +6.36%
Mar-15-18 05:05PM  Navidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech Industry Business Wire
Mar-09-18 04:26PM  Edited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 05:12PM  Navidea reports 4Q loss Associated Press
04:26PM  Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:15PM  Navidea Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 04:30PM  Navidea Biopharmaceuticals Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update Business Wire
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Latkin JedCEO, COO & CFOFeb 20Buy1.085,0005,40017,950Feb 20 04:39 PM
Scott John K Jr.10% OwnerFeb 13Buy0.852,373,5292,017,5008,042,162Feb 19 03:58 PM
Scott John K Jr.10% OwnerDec 06Buy0.90555,555500,0005,668,633Dec 11 11:11 AM
Scott John K Jr.10% OwnerJun 18Buy0.754,000,0003,000,0005,113,078Jun 21 08:50 PM
Latkin JedCEO, COO & CFOJun 05Buy1.261,0001,25812,950Jun 07 04:05 PM